AMLX — Amylyx Pharmaceuticals, Inc.

Summary of Amylyx Pharmaceuticals, Inc. Q4 2025 Earnings Call

1. Key Financial Results and Metrics

• Cash Position: Ended Q4 2025 with $317 million in cash and marketable securities, down from $344 million in Q3 2025. This provides a cash runway into 2028.
• Operating Expenses: Total operating expenses were $36.6 million, an 8% decrease from Q4 2024.
  • R&D Expenses: $21.2 million, down from $22.9 million in Q4 2024, primarily due to reduced spending on AMX035.
  • SG&A Expenses: $15.4 million, down from $17.1 million in Q4 2024, attributed to lower consulting and professional service costs.
• Stock-Based Compensation: Non-cash stock-based compensation was $6.4 million, compared to $6.8 million in the prior year.

2. Strategic Updates and Business Highlights

• Pipeline Advancement:
  • Initiated the pivotal Phase III LUCIDITY trial for Avexatide, targeting post-bariatric hypoglycemia (PBH).
  • AMX318, a long-acting GLP-1 receptor antagonist, was nominated as a development candidate.
  • AMX114 received Fast Track designation and progressed to the next cohort in the ALS Phase 1 LUMINA trial.
• Commercial Preparations: Focused on building commercial infrastructure and market access strategies for Avexatide, with plans for a potential launch in 2027.
• Market Research: Identified approximately 160,000 individuals living with PBH in the U.S., emphasizing the unmet medical need.

3. Forward Guidance and Outlook

• Upcoming Milestones:
  • Expect top-line data from the LUCIDITY trial in Q3 2026.
  • NDA preparations are underway to support a rapid submission post-data readout.
• Commercial Launch: If approved, Avexatide could be launched in 2027.

4. Bad News, Challenges, or Points of Concern

• Cash Decrease: The decline in cash reserves from the previous quarter may raise concerns about financial sustainability if expenses increase unexpectedly.
• Regulatory Risks: The success of the LUCIDITY trial is critical; any adverse results could impact the timeline for NDA submission and commercialization.
• Market Competition: There is no approved therapy for PBH currently, but the absence of competition also indicates the high stakes involved in successfully bringing Avexatide to market.

5. Notable Q&A Insights

• Clinical Trial Execution: The recruitment for the LUCIDITY trial is complete, with high participant interest. The company emphasized the significant unmet need for PBH treatment.
• Placebo Effect Concerns: The team discussed the statistical design of the LUCIDITY trial, addressing concerns about potential placebo effects based on previous trials.
• Market Dynamics: Insights from physicians indicate that any reduction in hypoglycemic events would be meaningful, reinforcing the urgency for effective treatment.
• ICD-10 Code Discussions: The potential introduction of an ICD-10 code for PBH is seen as a positive development that could enhance awareness and treatment pathways.

Overall, Amylyx Pharmaceuticals is positioned for a transformative year ahead, with a strong focus on advancing its pipeline and preparing for the commercial launch of Avexatide, while navigating the inherent risks of clinical development and market entry.